The effect of Hurricane Beryl on Houston's Johnson Space Center, home to the control centers for both NASA and Boeing, also contributed to the delay for NASA test pilots Butch Wilmore and Suni Williams. Photo via Boeing

Two astronauts who should have been back on Earth weeks ago said Wednesday that they’re confident that Boeing’s space capsule can return them safely, despite a string of vexing breakdowns.

NASA test pilots Butch Wilmore and Suni Williams launched aboard Boeing’s new Starliner capsule early last month, the first people to ride it. Helium leaks and thruster failures almost derailed their arrival at the International Space Station, and have kept them there much longer than planned. Now the earliest they could return may be the end of July, officials said.

In their first news conference from orbit, the pair said they expect to return once thruster testing is complete here on Earth. They said they’re not complaining about getting extra time in orbit, and are enjoying helping the station crew. Both have previously spent stints at the orbiting lab, which is also home to seven others.

“I have a real good feeling in my heart that the spacecraft will bring us home, no problem," Williams told reporters.

The test flight should have lasted eight days, ending on June 14.

NASA's commercial crew program director Steve Stich said the earliest the Starliner astronauts might return is the end of July. The goal is to get them back before SpaceX delivers a fresh crew in mid-August, but that, too, could change, he noted.

Hurricane Beryl slowed some of the work. Johnson Space Center in Houston, home to the control centers for both NASA and Boeing, was closed earlier this week to all but the most critical staff.

This week, NASA and Boeing are trying to duplicate the Starliner's thruster problems on a brand new unit at White Sands Missile Range in New Mexico, one of the prime landing sites in the U.S. western desert. The trouble is in the propulsion system, used to maneuver the spacecraft.

Five thrusters failed as the capsule approached the space station on June 6, a day after liftoff. Four have since been reactivated. Wilmore said there should be enough working thrusters to get him and Williams out of orbit. There are also bigger engines that could fill in, if necessary.

“That mantra you’ve heard, failure is not an option, that’s why we are staying here now," Wilmore said. “We trust that the tests that we’re doing are the ones we need to do to get the right answers, to give us the data that we need to come back.”

Boeing and NASA consider the ground tests essential to determine what might have gone wrong since that part of the capsule — the service module — is discarded before landing. The leaks also are located in this disposable section.

So far, testing has not replicated the hot temperatures reached during the flight, according to Stich. Managers want to make sure the suspect thrusters are not damaged, before bringing Starliner back. They were fired more frequently than anticipated early in the flight, and the extra demand on them may have caused them to fail, Stich noted.

At the same time, ground tests are being conducted to better understand the helium leaks, which could stem from bad seals. Officials have previously said there is ample helium left for the trip home.

Boeing's Mark Nappi stressed that in an emergency, Starliner and its crew could return right now. While the company does not believe the thrusters are damaged, "we want to fill in the blanks and run this test to assure ourselves of that."

NASA ordered up the Starliner and SpaceX Dragon capsules a decade ago for astronaut flights to and from the space station, paying each company billions of dollars. SpaceX's first taxi flight with astronauts was in 2020. Boeing's first crew flight was repeatedly delayed because of software and other issues.

There have been no discussions with SpaceX about sending up a rescue capsule, Stich said.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Greentown Labs names Lawson Gow as its new Houston leader

head of hou

Greentown Labs has named Lawson Gow as its Head of Houston.

Gow is the founder of The Cannon, a coworking space with seven locations in the Houston area, with additional partner spaces. He also recently served as managing partner at Houston-based investment and advisory firm Helium Capital. Gow is the son of David Gow, founder of Energy Capital's parent company, Gow Media.

According to Greentown, Gow will "enhance the founder experience, cultivate strategic partnerships, and accelerate climatetech solutions" in his new role.

“I couldn’t be more excited to join Greentown at this critical moment for the energy transition,” Gow said in a news release. “Greentown has a fantastic track record of supporting entrepreneurs in Houston, Boston, and beyond, and I am eager to keep advancing our mission in the energy transition capital of the world.”

Gow has also held analyst, strategy and advising roles since graduating from Rice University.

“We are thrilled to welcome Lawson to our leadership team,” Georgina Campbell Flatter, CEO of Greentown Labs, added in the release. “Lawson has spent his career building community and championing entrepreneurs, and we look forward to him deepening Greentown’s support of climate and energy startups as our Head of Houston.”

Gow is the latest addition to a series of new hires at Greentown Labs following a leadership shakeup.

Flatter was named as the organization's new CEO in February, replacing Kevin Dutt, Greentown’s interim CEO, who replaced Kevin Knobloch after he announced that he would step down in July 2024 after less than a year in the role.

Greentown also named Naheed Malik its new CFO in January.

Timmeko Moore Love was named the first Houston general manager and senior vice president of Greentown Labs. According to LinkedIn, she left the role in January.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.